• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of carcinogHomeBrowse articlesInstructionsSubmit articles
J Carcinog. 2009; 8: 10.
Published online Jun 2, 2009. doi:  10.4103/1477-3163.51851
PMCID: PMC2699605

Protein expression analysis of inflammation-related colon carcinogenesis

Abstract

Background:

Chronic inflammation is a risk factor for colorectal cancer (CRC) development. The aim of this study was to determine the differences in protein expression between CRC and the surrounding nontumorous colonic tissues in the mice that received azoxymethane (AOM) and dextran sodium sulfate (DSS) using a proteomic analysis.

Materials and Methods:

Male ICR mice were given a single intraperitoneal injection of AOM (10 mg/kg body weight), followed by 2% (w/v) DSS in their drinking water for seven days, starting one week after the AOM injection. Colonic adenocarcinoma developed after 20 weeks and a proteomics analysis based on two-dimensional gel electrophoresis and ultraflex TOF/TOF mass spectrometry was conducted in the cancerous and nontumorous tissue specimens.

Results:

The proteomic analysis revealed 21 differentially expressed proteins in the cancerous tissues in comparison to the nontumorous tissues. There were five markedly increased proteins (beta-tropomyosin, tropomyosin 1 alpha isoform b, S100 calcium binding protein A9, and an unknown protein) and 16 markedly decreased proteins (Car1 proteins, selenium-binding protein 1, HMG-CoA synthase, thioredoxin 1, 1 Cys peroxiredoxin protein 2, Fcgbp protein, Cytochrome c oxidase, subunit Va, ETHE1 protein, and 7 unknown proteins).

Conclusions:

There were 21 differentially expressed proteins in the cancerous tissues of the mice that received AOM and DSS. Their functions include metabolism, the antioxidant system, oxidative stress, mucin production, and inflammation. These findings may provide new insights into the mechanisms of inflammation-related colon carcinogenesis and the establishment of novel therapies and preventative strategies to treat carcinogenesis in the inflamed colon.

Keywords: Colitis-related carcinogenesis, mice, proteomics analysis

INTRODUCTION

Patients with chronic inflammatory bowel disease (IBD) including ulcerative colitis (UC) are at increased risk of developing colorectal cancer (CRC).[14] Indeed, IBD ranks among the top three high-risk conditions for CRC, together with familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC).[5] While the latter two hereditary diseases have a well-understood genetic etiology, CRC development in association with IBD appears to be closely relate to chronic inflammation of the large bowel mucosa. Also, IBD-associated colon carcinogenesis can be summarized as an inflammation-dysplasia-carcinoma sequence: hyperplastic lesions in the inflamed mucosa develop CRC through flat dysplasia.[6,7]

An azoxymethane (AOM)/dextran sodium sulfate (DSS) mouse model[8] was used to investigate the changes in global gene expression in the background of inflammation-related colon cancer.[9] A comprehensive DNA microarray analysis revealed that a number of genes altered their expression in the colonic mucosa of mice exposed to AOM/DSS and their expression was significantly increased or decreased in comparison to those found in the mice given AOM or DSS alone.[9] The number of genes with altered expression in the colonic mucosa of the mice that received AOM/DSS at week 5 was greater than that detected at week 10.[9] These genes showing their striking altered expression included Wif1, Plat, Myc, Plscr2, Pparbp, Tgfb3, and Pparg.[9]

Comparative proteomic analyses have been used for identifying proteins critical for phenotypic changes that occur during disease development.[10] A reproducible correlation is found between the expression patterns of multiple proteins within epithelial cells and the progression of neoplasms in a variety of tissues, such as the oral cavity,[11] prostate,[12] lung,[13,14] mammary gland,[15] liver,[16] and colon.[17] Yeo et al.[18] recently reported that a total of 38 proteins are differentially expressed in colonic tumors and normal mucosa of female C57BL/6 mice that received cycle treatment with DSS. They also stressed the importance of reduced expression of transgelin among the proteins as a biomarker of colitis-related colon carcinogenesis. However, they did not use a colonic carcinogen combined with DSS, rather they used a utilized cycle treatment with DSS to induce CRC in the inflamed colon.

The current study analyzed a number of proteins to isolate and identify tumor specific proteins that might be involved in the development of colitis-related CRC in AOM/DSS model mice[8] by two-dimensional gel electrophoresis to further investigate the protein expression during colitis-associated carcinogenesis.

MATERIALS AND METHODS

Animal experiments

Animals, chemicals, and diets

Male Crj: CD-1 (ICR) mice (Charles River Japan, Inc., Tokyo) aged five weeks were used in this study. AOM was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). DSS with a molecular weight of 36,000–50,000 (Cat. No. 160110) was obtained from MP Biomedicals, LLC (Aurora, OH, USA). DSS for the induction of colitis was dissolved in distilled water at a concentration of 2% (w/v). Charles River Formula (CRF)-1 (Oriental Yeast Co., Ltd., Tokyo, Japan) was used as a basal diet throughout the study.

Experimental procedure

After arriving, mice were acclimated for seven days with tap water and a pelleted basal diet of CRF-1, ad libitum. They received a single intraperitoneal (i.p.) injection of 10 mg/kg body weight AOM. Starting one week after the AOM injection, the animals were exposed to 2% DSS in the drinking water for seven days, and then were followed without any further treatment until the experiment was done. They were sacrificed by CO2 euthanasia at week 20 for the analysis. All mice were maintained at the Kanazawa Medical University Animal Facility according to the Institutional Animal Care Guidelines and were maintained under controlled conditions of humidity (50±10%), light (12/12 hr light/dark cycle), and temperature (23±2°C). The study protocol was approved by the Ethical Committee for animal experimentation of the Kanazawa Medical University.

Two-dimensional (2-D) gel electrophoresis

Chemicals

The sources for chemicals and materials used in the present study were: 3-([3 -Cholamidopropyl]-dimethylammonio)-1-propanesulfonate (CHAPS) from Wako Pure Chemicals (Osaka, Japan), N-decyl-N,N-dimethyl-3-ammonio-1-propane-sulfonate (SB3-10) from Sigma-Aldrich, ampholine from GE Healthcare UK Ltd. (Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, England), and all other chemicals were purchased from Wako Pure Chemicals.

2-D polyacrylamide gel electrophoresis (PAGE)

Colonic tumors (histologically confirmed as well-differentiated tubular adenocarcinomas) and nontumorous mucosa tissues were collected from the mice that received AOM and DSS and were stored at −80°C prior to use. The frozen tissues were homogenized with five volumes of lysis buffer (5 M urea, 2 M thiourea, 2% CHAPS, 2% SB3-10, 1% dithiothreitol, and 2% ampholine). The protein concentration of these samples was measured using a Protein Assay Kit (Bio-Rad Laboratories). The samples (100 μg) were applied overnight to Immobiline Drystrip (GE Healthcare Bio-Science) by in-gel rehydration.[19,20] The rehydrated gels were then gently dried with tissue paper to remove excess fluid and isoelectric focusing (IEF) was performed in a Multiphor II electrophoresis chamber (GE Healthcare Bio-Science) according to the manufacturer's instructions. Second dimension SDS-PAGE was performed in 9–18% acrylamide gradient gels using an IsoDalt electrophoresis chamber (GE Healthcare Bio-Science). The 2-D gels were stained with SYPRO Ruby (Bio-Rad Laboratories) under the manufacturer's protocols.[21] The SYPRO Ruby stained proteins were detected using the Molecular Imager FX (Bio-Rad Laboratories) and were subjected to in-gel digestion. Image analyses and database management were carried out using the ImageMaster 2D Platinum image analysis software program (GE Healthcare Bio-Science).

In-gel digestion and mass spectrometric identification of proteins

Protein spots were excised from the 2-D gels using clean scalpels, and were washed twice with Milli-Q water, and dehydrated in 100% acetonitrile (ACN) until they turned opaque white. The spots were then dried in a vacuum centrifuge, and subsequently rehydrated in 10 μl of digestion solution consisting of 50 mM NH4HCO3, 5 mM CaCl2, 0.01 μg/μl modified sequence-grade trypsin (Promega Co., Ltd.). After incubation for 16 hr at 37°C the digestion was terminated by adding 10 μl of 5% trifluoroacetic acid (TFA). The peptides were extracted three times for 20 mins with 50 μl of 5% TFA, 50% ACN, and the extracts were pooled and dried in a vacuum centrifuge. The dried materials were resuspended with 10 μl of 0.1% TFA. To remove excess salts from the extracts, solid-phase extraction was performed using C18 ZipTip (Millipore Co., Ltd.) according to the manufacturer's instructions. The peptides were eluted from the ZipTip by 3 μl of 50% ACN, 0.1% TFA and 1 μl of the eluants were spotted onto a target plate. Then, the spots on the target plate were immediately mixed with 0.5 μl of a matrix solution containing 0.3 mg/ml α-cyano-hydroxycinnamic acid, 33% acetone, 66% ethanol, and were completely air-dried at room temperature. MS and MS/MS spectra were obtained using an Ultraflex TOF/TOF mass spectrometer (Bruker Daltonics Co., Ltd.). An external peptide mixture was used to calibrate the instrument. Identification of proteins was carried out using the MASCOT software (Matrix Science Inc.) with the NCBInr database.

RESULTS

A comparative proteomic analysis was conducted on tumors or nontumorous mucosa specimens using 2-DE and MALDI-TOF. We identified 21 spots showing a more than 3.0-fold increase [Figure 1] or decrease [Figure 2] in density in the cancerous tissues. Following trypsin digestion, each spot was analyzed by MALDI-TOF MS, 4 [Table 1] and 9 [Table 2] proteins could be identified.

Figure 1
Two dimensional electrophoretic patterns of the whole cell proteins obtained from the cancerous tissues of the mice that received AOM/DSS. The gel was silver stained. The protein spots identified in this study are all circled.
Figure 2
Two dimensional electrophoretic patterns of whole cell proteins obtained from the inflamed colonic mucosa without any tumors in the mice that received AoM/dSS. Gel was silver stained. the protein spots identified in this study are all circle.
Table 1
Proteins that showed increased expression in the cancerous tissues of mice
Table 2
Proteins that showed decreased expression in the cancerous tissues of mice

The proteins with an increased expression in the cancerous tissues were beta-tropomyosin (8.41-fold increase), tropomyosin 1 alpha isoform b (7.28-fold increase), S100 calcium binding protein A9 (calgranulin B, 3.78-fold increase), peptidylprolylisomerase A (3.43-fold increase), and an unknown protein product (6.47-fold increase: Table 1). The proteins with decreased expression in the cancerous tissues were constitutive androstane receptor 1 (Car1) protein (17.08-fold decrease for spot 2298 and 5.45-fold decrease for spot 2251), Selenium-binding protein 1 (SELENBP1, 56 kDa selenium-binding protein, 7.39-fold decrease), 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase (5.39-fold decrease), thioredoxin 1 (4.77-fold decrease), 1-cys peroxiredoxin protein 2 (4.49-fold decrease), fcgbp protein (3.45-fold decrease), cytochrome c oxidase, subunit Va (3.38-fold decrease), and ETHE1 protein (3.09-fold decrease: Table 2). Seven other unknown proteins were also identified to show a decreased expression in the cancerous tissues [Table 2].

DISCUSSION

A comparative proteome analysis of CRC induced by AOM/DSS and the nontumorous mucosa revealed that a total of 21 demonstrated proteins (5 increased and 16 decreased expressions) altered their expression in the cancerous tissues in comparison to the nontumorous tissues. The number of proteins with altered expression was much smaller than genes that showed differential expression patterns in the previous DNA microarray analysis.[9] The proteins that showed altered expression in this study were not consistent with those reported by Yeo et al.[18] This discrepancy may be due to the differences of experimental designs between the two studies.

Car1 showed a 17.08-fold decrease for spot 2298 and 5.45-fold decrease for spot 2251 in the cancerous tissue in comparison to the nontumorous tissue. The constitutive androstane receptor (CAR, MB67NR1I3) is a member of the nuclear receptor (NR) superfamily.[22] The expression is most prevalent in the liver, where it mediates the induction of drug and endobiotic metabolism through a mechanism involving the direct regulation of genes encoding biotransformation enzymes.[23,24] Specifically, CAR targets include genes encoding phase I and phase II drug metabolizing functions as well as drug transport genes.[25] The nuclear pregnane X receptor (PXR) and CAR play central roles in protecting the body against environmental xenobiotics.[26] PXR and CAR are activated by a wide range of xenobiotics and regulate cytochrome P450 (CYP) and other genes whose products are involved in the detoxification of these chemicals. Using microarray analyses, a number of CAR-regulated genes have been elucidated,[26] and many of these seem to be directly involved in the metabolism and transport of xenobiotics.[27,28] The expression of many genes involved in xenobiotic/drug metabolism and transport are regulated by at least three nuclear receptors or xenosensors: CAR, PXR, and aryl hydrocarbon receptor. These receptors establish crosstalk with other nuclear receptors or transcription factors controlling signaling pathways that regulate the homeostasis of bile acids, lipids, glucose, inflammation, vitamins, hormones, and others. In the CYP profiles of colon carcinogenesis, significantly higher levels of several CYPs, such as CYP1B1, CYP2S1, CYP2U1, CYP3A5, and CYP51 are present in primary CRC, while CYP3A4 is the most frequently expressed in the normal colon.[29] However, CYP 3A expression is altered in the experimental colitis.[30] While the role of CYPs in IBD is not known, NR is involved in the mediation of inflammatory processes and therefore may play a role in the development of IBD.[31,32] In fact, a significant down-regulation of PXR and the PXR target gene, MDR1, is observed in healthy mucosa adjacent to diseased colonic and terminal ileum of patients with CD and UC.[32] Transgenic mice that do not express the MDR1 gene spontaneously develop colitis under specific pathogen-free conditions and the pathological picture of the colon is quite similar to severe intestinal inflammation observed in IBD.[31] The finding that the expression of CAR1 protein markedly decreased in the cancerous tissue in this study suggests that the decreasing expression of CAR1 protein causes down-regulation of the expression of the metabolism and transport of xenobiotics, such as CYP3A4 or MDR1. The comprehensive DNA microarray analysis using colonic mucosa of AOM/DSS treated and untreated mice,[9] revealed that certain CYP families (CYP2d26, CYP4f16, and CYP2c55) was down-regulated in the colonic mucosa of mice that received AOM/DSS. Thus, CYP may play an important role of the inflammation-related colon carcinogenesis.

HMG-CoA synthase demonstrated a 5.39-fold decrease in the cancerous tissue in this study. HMG-CoA synthase catalyzes a committed step in the pathways for isoprenoid, cholesterol, and ketone body production.[33] Cytosolic HMG-CoA synthase, mainly associated with the production of cholesterol and isoprenoid, is expressed expresses in many tissues and it has a negative feedback mechanism with the accumulation of intracellular cholesterol, which is partly regulated by sterol-regulatory element-binding protein (SREBP),[34] the same as HMG-CoA reductase. Recently, a HMG-CoA reductase inhibitor is reported to activate the transcription of cytosolic HMG-CoA synthase via SREBP.[35] Dietary pitavastatin inhibited AOM/DSS-induced colon carcinogenesis in our previous study,[36] suggesting that HMG-CoA synthase is involved in inflammation-related colon carcinogenesis. On the other hand, mitochondrial HMG-CoA synthase, in which is associated with the production of ketone, is mainly expressed in the liver and intestine. Fasting, cAMP, and fatty acids increase its transcriptional rate, while refeeding and insulin repress the rate.[37] Unlikely cytosolic HMG-CoA synthase, mitochondrial HMG-CoA synthase is regulated by peroxisomal proliferators regulatory element (PPRE), but not SREBP. The regulation of mitochondrial HMG-CoA synthase gene expression by fatty acids is mediated through PPRE, to which peroxisome proliferators activated receptor (PPAR) can bind.[38] PPAR is involved in colorectal oncogenesis.[39] Previously, we reported that dietary administration of ligands for PPARγ and α effectively suppressed the development of colonic epithelial malignancies induced by AOM/DSS in female ICR mice.[40]

The current study showed that Thioredoxin-1 (Trx), a 12kDa protein, was down-regulated by 4.77-fold in the cancerous tissues. This protein is located in the cytoplasm and when translocated into the nucleus has antioxidative and redox-regulating functions. Oxidative stress can be defined as the imbalance between cellular oxidant species production and antioxidant capability. Reactive oxygen species (ROS) are involved in a variety of different cellular processes ranging from apoptosis and necrosis to cell proliferation and carcinogenesis.[4,41] Intracellular Trx regulates DNA binding of several transcription factors including p53, nuclear factor (NF)-κB, and activator protein (AP)-1.[42] In our previous studies, NF-κB is highly expressed in colonic cancer induced by AOM/DSS and certain modulatory agents of its expression inhibit CRC development in the inflamed colon.[41,43,44] In addition, circulating Trx inhibits neutrophil infiltration into the sites of inflammation.[45] These findings suggest that Trx thus plays an important role, not only as an antioxidant and anti-apoptotic molecule, but also as an anti-inflammatory molecule. Therefore, Trx can be a good marker for oxidative stress in various diseases.[4648] Recently, serum Trx level was reported to be significantly higher in IBD patients and its levels correlated with disease activity.[49] Trx-overexpressing transgenic mice show a decreased severity of colitis in mice treated with DSS.[49] Moreover, the administration of recombinant human Trx decreases the severity of colonic inflammation in interleukin (IL)-10 KO mice.[49] These findings strongly suggest that Trx is involved in the pathophysiology of IBD. Alteration of Trx expression is involved in colitis-related carcinogenesis via regulating DNA binding activity of several transcription factors, including p53, NF-κB, and AP-1 or gene expression associated with inflammation or apoptosis. The other proteins which showed decreased expression in the tumor tissue included Selenium-binding protein 1, HMG CoA synthase, 1-Cys peroxiredoxin protein 2, Fcgbp protein, Cytochrome c oxidase, subunit Va, and ETHE1 protein.

We also observed that the proteins showed highly increased expression in the tumor tissue. The expression of β-tropomyosin and tropomyosin 1 were highly increased by 8.41-fold (spot no. 1915) and 7.28-fold (spot no. 1868), respectively, in the cancer tissue in comparison to the nontumorous tissue. Tropomyosin (TM) is an actin-binding protein, which is localized head to tail along the length of the actin filament and controls cell motility.[50] Although the role of TMs in muscle contraction is well known, their role in nonmuscle cells is less clear. Several lines of evidence suggest that high molecular weight (HMW) TMs encoded by TPM-1 (α-TM) and TPM-2 (β-TM) genes[51] may contribute to the tumor suppressor activity of TGF-β.[52] Bakin et al.[52] reported that induction of TMs and stress fibers play an essential role in TGF-β-control of cell motility, and the loss of this TGF-β-response is a critical step in the acquisition of a metastatic phenotype by tumor cells. TMs are involved in pathogenesis of IBD, UC, and CD,[5355] although the role in colitis-related colon oncogenesis is not known. Other proteins that were highly expressed in the tumor tissue were S100 calcium binding protein A9 and Peptidylprolylisomerase A.

In conclusion, the proteomes of CRC and that of nontumorous mucosa of mice that received AOM and DSS were compared in gels, and differentially expressed proteins were identified by mass spectrometry. A total of 13 proteins from 21 spots were identified by 2-DE and MALDI-TOF MS. Among 13 proteins which showed different expression, CAR1, a member of nuclear receptor superfamily, may play an especially important role in this carcinogenesis model as it showed the most drastic decrease. The study of the protein expression in the tumor tissue and nontumorous mucosa in colitis-associated cancer of a mice model (AOM/DSS model) may help us to find tumor-specific proteins for understanding the pathogenesis of colitis-associated cancer development. Proteomic technologies can thus be used to design rational drugs according to the molecular profile of the cancer cells, and thereby facilitate the development of personalized cancer therapy and prevention.

CONCLUSIONS

There were 21 proteins differently expressed in the cancerous tissues of mice that received AOM and DSS. Their functions included metabolism, the antioxidant system, oxidative stress, mucin production, and inflammation. This is the first report describing a comprehensive protein expression analysis in an AOM/DSS-induced mouse colon carcinogenesis model. These findings may provide new insights into the mechanisms of inflammation-related colon carcinogenesis and the establishment of novel therapies and preventative strategies against carcinogenesis in inflamed colonic tissue.

AUTHOR'S PROFILE

An external file that holds a picture, illustration, etc.
Object name is JC-08-51851-g003.jpg

Dr. TAKUJI TANAKA, M.D., Ph.D., FIAC

1978 - 1983: Assistant Professor, Department of Pathology, Gifu University School of Medicine, Japan

1983 - 1985: Visiting Scientist, Division of Experimental Pathology and Toxicology, Naylor Dana Institute, American Health Foundation, New York, USA

1985 - 1997: Associate Professor, Department of Pathology, Gifu University School of Medicine, Japan

1997 -: Professor and Chairman, Department of Oncologic Pathology, Kanazawa Medical University, Japan

Specialty and Present Interest:

Inflammation and Cancer; Cancer chemoprevention by natural products; Biomarkers of carcinogenesis and cancer chemoprevention; Chemical carcinogenesis

Memberships for Academic Societies:

Japanese Cancer Association (1976-; Councilor, 2000-)

Japanese Society of Pathology (1976-; Councilor, 1986-)

Japanese Society of Toxicologic Pathology (1986-)

International Academy of Pathology (1987-)

International Academy of Cytology (MIAC, 1987-; FIAC, 1989-)

American Association for Cancer Research (1989-)

European Association for Cancer Research (1991-)

Editorial Board:

Journal of Carcinogenesis (Sr. Editor)

Molecular Carcinogenesis

Chemico-Biological Interactions

Asian Pacific Journal of Cancer Prevention

The Open Toxicology Journal

Journal of Toxicologic Pathology

Japanese Journal of Food Chemistry

Journal of Toxicological Sciences (Associate Editor)

REFERENCES

1. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276–85. [PubMed]
2. Lashner BA, Provencher KS, Bozdech JM, Brzezinski A. Worsening risk for the development of dysplasia or cancer in patients with chronic ulcerative colitis. Am J Gastroenterol. 1995;90:377–80. [PubMed]
3. Miyamoto S, Yasui Y, Murakami A, Tanaka T. Molecular mechanism of colorectal carcinogenesis. In: Tanaka T, editor. Cancer: Disease Progression and Chemoprevention Kerala (India): Research Signpost. 2007. pp. 45–56.
4. Yasui Y, Kim M, Oyama T, Tanaka T. Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets. Curr Enzyme Inhibition. 2009;5:1–26.
5. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–17. [PubMed]
6. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378–89. [PMC free article] [PubMed]
7. Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008;14:2662–9. [PMC free article] [PubMed]
8. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94:965–73. [PubMed]
9. Suzuki R, Miyamoto S, Yasui Y, Sugie S, Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer. 2007;7:84. [PMC free article] [PubMed]
10. Hanash SM. Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther. 2001;3:538–45. [PubMed]
11. Hu S, Wong DT. Oral cancer proteomics. Curr Opin Mol Ther. 2007;9:467–76. [PubMed]
12. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate. 2002;50:54–63. [PubMed]
13. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61:7908–12. [PubMed]
14. Oh JM, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, et al. A database of protein expression in lung cancer. Proteomics. 2001;1:1303–19. [PubMed]
15. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, et al. New approaches to proteomic analysis of breast cancer. Proteomics. 2001;1:1205–15. [PubMed]
16. Sun W, Xing B, Sun Y, Du X, Lu M, Hao C, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics. 2007;6:1798–808. [PubMed]
17. Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn. 2005;5:353–75. [PubMed]
18. Yeo M, Kim DK, Park HJ, Oh TY, Kim JH, Cho SW, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics. 2006;6:1158–65. [PubMed]
19. Sanchez JC, Rouge V, Pisteur M, Ravier F, Tonella L, Moosmayer M, et al. Improved and simplified in-gel sample application using reswelling of dry immobilized pH gradients. Electrophoresis. 1997;18:324–7. [PubMed]
20. Rabilloud T, Valette C, Lawrence JJ. Sample application by in-gel rehydration improves the resolution of two-dimensional electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis. 1994;15:1552–8. [PubMed]
21. Lopez MF, Berggren K, Chernokalskaya E, Lazarev A, Robinson M, Patton WF. A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis. 2000;21:3673–83. [PubMed]
22. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866–70. [PubMed]
23. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev. 2003;55:649–73. [PubMed]
24. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet. 2003;42:1331–57. [PubMed]
25. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28:249–68. [PubMed]
26. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol. 2002;62:638–46. [PubMed]
27. Moreau A, Vilarem MJ, Maurel P, Pascussi JM. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm. 2008;5:35–41. [PubMed]
28. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: Crosstalk and consequences. Annu Rev Pharmacol Toxicol. 2008;48:1–32. [PubMed]
29. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, et al. Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin Cancer Res. 2005;11:3758–65. [PubMed]
30. Pellequer Y, Weissenborn V, Lamprecht A. Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis. J Pharm Sci. 2007;96:2145–53. [PubMed]
31. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr la, spontaneously develop colitis. J Immunol. 1998;161:5733–44. [PubMed]
32. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, et al. Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26–40. [PubMed]
33. Leonard S, Sinensky M. Somatic cell genetics and the study of cholesterol metabolism. Biochim Biophys Acta. 1988;947:101–12. [PubMed]
34. Dooley KA, Millinder S, Osborne TF. Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. J Biol Chem. 1998;273:1349–56. [PubMed]
35. Mascaro C, Ortiz JA, Ramos MM, Haro D, Hegardt FG. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription. Arch Biochem Biophys. 2000;374:286–92. [PubMed]
36. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, et al. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer. 2007;121:2331–9. [PubMed]
37. Hegardt FG. Transcriptional regulation of mitochondrial HMG-CoA synthase in the control of ketogenesis. Biochimie. 1998;80:803–6. [PubMed]
38. Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem. 1994;269:18767–72. [PubMed]
39. Yasui Y, Kim M, Tanaka T. PPAR Ligands for Cancer Chemoprevention. PPAR Res. 2008;2008:548919. [PMC free article] [PubMed]
40. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer. 2005;5:46. [PMC free article] [PubMed]
41. Tanaka T, Yasui Y, Ishigamori-Suzuki R, Oyama T. Citrus compounds inhibit inflammation- and obesity-related colon carcinogenesis in mice. Nutr Cancer. 2008;60:70–80. [PubMed]
42. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct. 2001;30:421–55. [PubMed]
43. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A, Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer. 2009;124:264–71. [PubMed]
44. Tanaka T, Yasui Y, Tanaka M, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact. 2009;177:128–36. [PubMed]
45. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A. 2001;98:15143–8. [PMC free article] [PubMed]
46. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA. Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci U S A. 2001;98:2688–93. [PMC free article] [PubMed]
47. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol. 2000;33:616–22. [PubMed]
48. Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: Its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol. 1999;163:351–8. [PubMed]
49. Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, et al. Human thioredoxin-I ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology. 2006;131:1110–21. [PubMed]
50. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev. 2001;11:41–7. [PubMed]
51. Schleef M, Werner K, Satzger U, Kaupmann K, Jockusch H. Chromosomal localization and genomic cloning of the mouse alpha-tropomyosin gene Tpm-I. Genomics. 1993;17:519–21. [PubMed]
52. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H, Helfman DM. A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell. 2004;15:4682–94. [PMC free article] [PubMed]
53. Das KM, Bajpai M. Tropomyosins in human diseases: ulcerative colitis. Adv Exp Med Biol. 2008;644:158–67. [PubMed]
54. Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, et al. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912–22. [PubMed]
55. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol. 2004;11:195–204. [PMC free article] [PubMed]

Articles from Journal of Carcinogenesis are provided here courtesy of Medknow Publications

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...